These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 775542)

  • 41. Inhibition of drug metabolism by chronically administered naltrexone.
    Lehman TM; Pyati P; Peterson GR
    Life Sci; 1979 Oct; 25(18):1591-600. PubMed ID: 522615
    [No Abstract]   [Full Text] [Related]  

  • 42. The effect of indomethacin on hepatic drug-oxidizing capacity in the rat: trimethadione and antipyrine metabolism as an indicator.
    Tanaka E; Kobayashi S; Aramphongphan A; Kurata N; Oguchi K; Kuroiwa Y; Yasuhara H
    J Pharmacobiodyn; 1985 Sep; 8(9):773-9. PubMed ID: 4087137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in rabbits with experimental renal failure.
    van Peer AP; Belpaire FM; Bogaert MG
    Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):346-7. PubMed ID: 708161
    [No Abstract]   [Full Text] [Related]  

  • 44. Multiple drug metabolism in hepatic subcellular fractions.
    Muakkassah SF; Lowery GL; Bidlack WR
    Proc West Pharmacol Soc; 1979; 22():119-24. PubMed ID: 515040
    [No Abstract]   [Full Text] [Related]  

  • 45. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.
    Murray M
    Drug Metab Rev; 1987; 18(1):55-81. PubMed ID: 3311684
    [No Abstract]   [Full Text] [Related]  

  • 46. Categorization of lipophilic xenobiotics by the enthalpic structure-function response of hepatic mixed-function oxidase.
    Hollebone BR
    Drug Metab Rev; 1986; 17(1-2):93-143. PubMed ID: 3536381
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical importance of hepatic cytochrome P450 in drug metabolism.
    Spatzenegger M; Jaeger W
    Drug Metab Rev; 1995; 27(3):397-417. PubMed ID: 8521748
    [No Abstract]   [Full Text] [Related]  

  • 48. Drugs and the ageing liver.
    James OF
    J Hepatol; 1985; 1(4):431-5. PubMed ID: 3902953
    [No Abstract]   [Full Text] [Related]  

  • 49. Impairment of drug metabolism in man by allopurinol and nortriptyline.
    Vesell ES; Passananti GT; Greene FE
    N Engl J Med; 1970 Dec; 283(27):1484-8. PubMed ID: 4098480
    [No Abstract]   [Full Text] [Related]  

  • 50. Kinetics of hepatic cytochrome P-450-dependent mono-oxygenase systems.
    Gander JE; Mannering GJ
    Pharmacol Ther; 1980; 10(2):191-221. PubMed ID: 6997897
    [No Abstract]   [Full Text] [Related]  

  • 51. [Changes in the effect of drugs due to reciprocal interference with their protein binding and catabolism].
    Remmer H
    Dtsch Med Wochenschr; 1974 Mar; 99(9):413-9. PubMed ID: 4857236
    [No Abstract]   [Full Text] [Related]  

  • 52. Hepatic drug-metabolizing enzymes in lung tumor-bearing rats.
    Dogra SC; Khanduja KL; Sharma RR
    Biochem Pharmacol; 1985 Sep; 34(17):3190-3. PubMed ID: 4038331
    [No Abstract]   [Full Text] [Related]  

  • 53. Experimental in vitro approach to the study of covalent associations.
    Pantarotto C
    Food Addit Contam; 1984; 1(2):131-46. PubMed ID: 6536525
    [No Abstract]   [Full Text] [Related]  

  • 54. In vitro methods for assessing human hepatic drug metabolism: their use in drug development.
    Wrighton SA; Vandenbranden M; Stevens JC; Shipley LA; Ring BJ; Rettie AE; Cashman JR
    Drug Metab Rev; 1993; 25(4):453-84. PubMed ID: 8313838
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibitory effect of tranylcypromine on hepatic drug metabolism in the rat.
    Bélanger PM; Atitśe-Gbeassor A
    Biochem Pharmacol; 1982 Aug; 31(16):2679-83. PubMed ID: 7138562
    [No Abstract]   [Full Text] [Related]  

  • 56. Role of human hepatic cytochromes P450 in drug metabolism and toxicity.
    George J; Farrell GC
    Aust N Z J Med; 1991 Jun; 21(3):356-62. PubMed ID: 1953519
    [No Abstract]   [Full Text] [Related]  

  • 57. [Genetic polymorphism of drug oxidation].
    Heller FR; Leclercq V; Harvengt C
    Acta Gastroenterol Belg; 1988; 51(1):91-101. PubMed ID: 3055790
    [No Abstract]   [Full Text] [Related]  

  • 58. Drugs in liver disease.
    Branch RA
    Clin Pharmacol Ther; 1998 Oct; 64(4):462-5. PubMed ID: 9797803
    [No Abstract]   [Full Text] [Related]  

  • 59. Lithium-induced increase in the metabolism of benzo[a]pyrene and drugs in rat liver.
    Feuerstein G; Govrin H; Kapitulnik J
    Biochem Pharmacol; 1979 Nov; 28(21):3167-70. PubMed ID: 118760
    [No Abstract]   [Full Text] [Related]  

  • 60. A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites.
    Vessell ES; Penno MB
    Biochem Soc Trans; 1984 Feb; 12(1):74-8. PubMed ID: 6705993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.